Pembrolizumab Injection [Keytruda]

DRUG16 trials

Sponsors

University of California, Irvine, Yana Najjar, Inge Marie Svane, SMT bio Co., Ltd., CHA University

Conditions

Adenocarcinoma of Esophagogastric JunctionAdjuvant TreatmentAdvanced Biliary Tract CarcinomaAdvanced MelanomaAdvanced Solid TumorBiliary Tract CancerBiochemical Recurrence of Malignant Neoplasm of ProstateBreast Cancer

Phase 1

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

WithdrawnNCT03189186

University of California, IrvineMetastatic Kidney Cancer, Renal Cell Carcinoma

Start: 2017-07-01End: 2018-10-17Updated: 2021-04-05

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

RecruitingNCT03311308

Yana NajjarAdvanced Melanoma

Start: 2018-02-07End: 2029-12-31Target: 30Updated: 2025-05-06

Allogeneic NK Cell (SMT-NK) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

CompletedNCT03937895

SMT bio Co., Ltd.Biliary Tract Cancer

Start: 2019-12-03End: 2021-06-08Updated: 2022-03-29

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

CompletedNCT04659629

Neurogene Inc.Advanced Solid Tumor, Solid Tumor

Start: 2021-04-26End: 2024-08-15Updated: 2024-10-01

Phase 2

Melanoma Metastasized to the Brain and Steroids

RecruitingNCT03563729

Inge Marie SvaneMalignant Melanoma

Start: 2018-06-06End: 2028-06-06Target: 80Updated: 2023-07-13

Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)

CHA UniversityGestational Trophoblastic Neoplasia

Start: 2020-06-01End: 2023-05-01Target: 15Updated: 2020-03-11

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

Tianjin Medical University Cancer Institute and HospitalEsophageal Squamous Cell Carcinoma, Stage III

Start: 2020-07-08End: 2024-12-31Target: 50Updated: 2023-04-10

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

CompletedNCT04550624

Shanghai Jiahui International HospitalAdvanced Biliary Tract Carcinoma

Start: 2021-09-15End: 2025-12-02Updated: 2026-01-21

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

Tianjin Medical University Cancer Institute and HospitalAdenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab

Start: 2021-04-01End: 2024-03-31Target: 30Updated: 2021-03-24

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

Tianjin Medical University Cancer Institute and HospitalAdjuvant Treatment, ESCC, Lymph Node Positive +1

Start: 2021-05-01End: 2024-04-30Target: 82Updated: 2021-04-28

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

RecruitingNCT04931979

Prof. Dr. med. Christian GratzkeBiochemical Recurrence of Malignant Neoplasm of Prostate, Urologic Cancer

Start: 2022-10-20End: 2026-04-01Target: 49Updated: 2023-03-01

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Active, not recruitingNCT05033756

Institut fuer FrauengesundheitBreast Cancer, Malignant Neoplasm of Breast

Start: 2022-07-30End: 2026-02-28Updated: 2024-05-07

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

RecruitingNCT05096390

Centre Leon BerardPapillary Renal Cell Carcinoma Type 2

Start: 2022-06-01End: 2026-06-30Target: 72Updated: 2024-01-25

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

RecruitingNCT06180733

University Medical Center GroningenEndometrial Cancer

Start: 2023-12-01End: 2028-01-31Target: 12Updated: 2023-12-22

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

Not yet recruitingNCT06646445

GERCOR - Multidisciplinary Oncology Cooperative GroupColon Cancer

Start: 2025-09-30End: 2029-12-31Target: 60Updated: 2025-06-13

Unknown Phase

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant

RenJi HospitalHepatocellular Carcinoma Recurrent, Liver Transplant; Complications

Start: 2020-08-06End: 2024-12-30Target: 192Updated: 2020-08-13

Related Papers

Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study

Liver Research2025-03-082 citations

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

2024-10-2728 citations

Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.

Journal of Clinical Oncology2023-06-011 citations

Abstract CT250: A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer

Cancer Research2022-06-152 citations

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)

Frontiers in Oncology2022-03-3155 citations

Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.

Journal of Clinical Oncology2022-02-161 citations

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Annals of Translational Medicine2022-02-0159 citations

509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer

Regular and Young Investigator Award Abstracts2021-11-014 citations

716 NL-201 induces inflammation in a 'cold' tumor microenvironment through upregulation of MHC-I, expansion of the TCR repertoire, and potent antitumor activity when combined with PD-1 inhibition

Regular and Young Investigator Award Abstracts2021-11-01

563 ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation

Regular and Young Investigator Award Abstracts2021-11-01

Abstract CT171: Combinatorial allogeneic NK cell therapy with Pembrolizumab for cholangiocarcinoma; interim report of open label Phase1/2a study

Cancer Research2021-07-012 citations